BCIwiki — Brain-computer interface news, research and industry database

Barcelona-based INBRAIN Neuroelectronics said it will work with Microsoft on AI for neurology and brain-computer interfaces, combining INBRAIN's neuroscience, bioelectronics and AI work with Microsoft's cloud and AI infrastructure. INBRAIN's graphene-based neural interface is being developed as an adjunctive therapy for Parkinson's disease; it received FDA breakthrough device designation in 2023 and entered its first-in-human study in the fall of 2025.

The study involves no implant and tests no device. It asks 50 adults with acquired blindness what existing assistive devices get wrong, and what they would want from a vision-restoration implant. Outcomes span demographics and economics, quality of life, clinical features, satisfaction with current aids, and design requirements for an invasive visual brain-computer interface. Participants must be at least 18, have only weak or no light perception in both eyes, and have lost their sight after birth; congenital blindness is excluded.

Seven Chinese ministries led by MIIT issued guidelines targeting breakthroughs in core BCI technologies by 2027 — including electrodes, chips, and integrated devices at internationally competitive levels — with accelerated deployment in manufacturing, healthcare, and consumer markets. By 2030, the plan calls for cultivating 2–3 globally influential BCI companies and building an internationally competitive industry ecosystem.

A perspective review published in Computers in biology and medicine examines EEG non-stationarity across sessions, people, and recording conditions. It asks whether mechanisms that help the brain maintain functional stability can improve the robustness of brain-computer interface models. The review covers synaptic plasticity, homeostatic regulation, neural oscillations, and spiking representations, comparing bio-inspired approaches with conventional machine learning and transfer learning. It also considers hybrid designs that combine biologically grounded mechanisms with artificial neural networks. The author proposes operational definitions for bio-inspired, bio-plausible, and bio-realistic modeling, together with a minimum specification for continual EEG benchmarks. Because direct EEG evidence remains limited for several proposed mechanisms, the review stresses the need to distinguish empirical findings from hypotheses and future research directions.

The FDA cleared Universal Brain's UB ERP System on June 30, 2026, finding it substantially equivalent under submission number K253767 through the traditional 510(k) pathway. The agency classifies it as Non-Normalizing Quantitative Electroencephalograph Software, a Class II device under regulation 882.1400, with neurology as the assigned review panel. Event-related potentials are obtained by averaging EEG time-locked to stimuli; components such as P300 serve both clinical assessment and the classic paradigms behind noninvasive BCI spellers.

The FDA cleared the Ceribell Monitor on June 30, 2026, finding it substantially equivalent under submission number K261101 through the traditional 510(k) pathway. The agency classifies it as a Reduced-Montage Standard Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. It is one of several Ceribell clearances in the same period; the product line is built around rapid reduced-montage setup for bedside recording in emergency and critical care.

The FDA approved a premarket approval (PMA) supplement, S039, from Saluda Medical Pty, Ltd. on June 29, 2026, covering the CAP24 Paddle Lead, Passing Elevator, Evoke CLS (REF 3042), Clarity Programming Application (CPA) and RECAP Viewer. The supplement is a labeling change touching indications, instructions for use, shelf life and trade name rather than an original approval of a new device; the products carry the generic name 'stimulator, spinal-cord, totally implanted for pain relief.' Saluda Medical is an Australian company whose Evoke system is one of the few closed-loop spinal cord stimulators on the market.